GlassScriptPhysician profile
Jerry A Stallings
NPI 1669623609
$7,114.88
in general payments reported to CMS, 2019-2025
35 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,062 · 2022: $1,292 · 2023: $1,140 · 2024: $1,483 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,760.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,177.57 | 2021-2025 | |
| Novo Nordisk INC | $819.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $582.81 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $448.07 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $356.23 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $295.47 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $239.50 | 2021-2025 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $236.59 | 2022-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $218.49 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.14 | 2022-2025 | Caplyta |
| Pfizer INC. | $184.46 | 2021-2025 | |
| Dexcom, INC. | $163.40 | 2022-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $125.52 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $113.52 | 2021-2022 | |
| Esperion Therapeutics, INC. | $107.55 | 2021-2025 | Nexletol |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $106.30 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $95.00 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $90.99 | 2021-2024 | |
| Abbott Laboratories | $89.99 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $70.71 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $66.08 | 2021-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.09 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $40.35 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.17 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $35.16 | 2021 | |
| Lundbeck LLC | $30.13 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $28.11 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $21.49 | 2024 | Fanapt, Hetlioz |
| Urovant Sciences INC | $20.42 | 2021 | |
| Ucb, INC. | $16.81 | 2021 | |
| Neurocrine Biosciences, INC. | $14.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.88 | 2025 | Zoryve |
| Ironwood Pharmaceuticals, INC | $14.36 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.43 | 2023 | Quviviq |
| Genentech USA, INC. | $3.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Stallings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.